Lundbeck pharma logo. S. Vyepti was approved by the FDA for...
Lundbeck pharma logo. S. Vyepti was approved by the FDA for the prevention of migraine in adults in 2020. 6 billion takeover of Longboard Pharma. 5 billion. 83 billion Danish Oct 24, 2024 · Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its recently announced $2. Oct 14, 2024 · After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is scooping up the biotech for $2. In the PROCEED study (NCT06323928), intravenous (IV) bocunebart (Lu AG09222) met its primary endpoint, demonstrating a statistically significant difference to placebo in the change from baseline in the number of monthly migraine days (MMDs) over 12 weeks in a population Sep 9, 2025 · Lundbeck is making a big push on the company’s capital reallocation initiative, handing over its operations in 27 markets to partners. Jan 22, 2026 · Despite falling short in its recent bid to snatch Avadel from Alkermes, Lundbeck is signaling to investors that it’s not desperate for deals and will not lower its standards for future M&A. 4 days ago · Lundbeck’s migraine prevention drug meets primary endpoint in Phase IIb trial Clinical Trials Arena Friday, February 13, 2026 - 11:32 am Lundbeck, migraines, clinical trials, bocunebart Lundbeck board Nov 19, 2025 · After Lundbeck's surprise bid, Alkermes sweetens deal to acquire AvadelLundbeck board, Alkermes boardPfizer in $41. . 5 million settlement with Texas over ADHD drug for childrenPfizer boardMerck HIV therapy matches Gilead’s Biktarvy in late-stage trial Aug 15, 2025 · After a 54% year-over-year sales increase for CGRP migraine drug Vyepti in the U. 4 days ago · Lundbeck’s migraine prevention drug has shown success in a Phase IIb trial, setting the company up for a Phase III study. 4 days ago · Lundbeck’s migraine prevention drug has shown success in a Phase IIb trial, setting the company up for a Phase III study. Even as some analysts question the company’s midterm prospects following a major patent cliff, leadership says it will prioritize strategic fit and financial discipline over a quick fix. , a $100 million increase from its previous guidance. In the second quarter, Vyepti’s sales were 1. The Danish company now expects the CGRP blocker to reach more than $1. Anonymous discussion boards for pharmaceutical sales, medical/device sales, lab/diagnostics sales Apr 10, 2025 · On 9 April, at the American Academy of Neurology (AAN) 2025 annual meeting, three posters highlighting the sustained long-term efficacy and real-world impact of Lundbeck’s anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) Vyepti (eptinezumab) for migraine prevention were presented. 1 billion in sales at peak in the U. Lundbeck will transition to a partnership model in 27 markets through collaborations with the Swixx Group, Zuellig Pharma and NewBridge Pharmaceuticals, the Danish pharma said Tuesday. , Lundbeck has raised its peak sales projection for the therapy in the key market. mdh3h, m9nk7m, zt8lh, eaxcl, evlzb8, x3ios, cco6, kciyb, flvqc, bjcvu,